Macrophage migration inhibitory factor deficiency protects pancreatic islets from cytokine-induced apoptosis in vitro

Clinical and Experimental Immunology

Volumn 169, Issue 2, 2012, Pages 156-163

  Stojanovic, I ^a   Saksida, T ^a   Nikolic, I ^a   Nicoletti, F ^b   Stosic Grujicic, S ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Apoptosis; Diabetes; IL 1 ; Macrophage migration inhibitory factor (MIF); Pancreatic islets

Indexed keywords

CASPASE 3; CYCLOOXYGENASE 2; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; INSULIN SYNTHESIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CYTOKINES; ENZYME ACTIVATION; INFLAMMATION MEDIATORS; ISLETS OF LANGERHANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3;

EID: 84863565284     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04607.x     Document Type: Article

References (43)

1. Beyan H, Buckley LR, Yousaf N, Londei M, Leslie RD. A role for innate immunity in type 1 diabetes? Diabetes Metab Res Rev 2003; 19:89-100.
2. Kaminitz A, Stein J, Yaniv I, Askenasy N. The vicious cycle of apoptotic β-cell death in type 1 diabetes. Immunol Cell Biol 2007; 85:582-9.
3. Pirot P, Cardozo AK, Eizirik DL. Mediators and mechanisms of pancreatic beta-cell death in type 1 diabetes. Arq Bras Endocrinol Metabol 2008; 52:156-65.
4. Davi G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal 2005; 7:256-68.
5. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009; 5:219-26.
6. Cardozo AK, Heimberg H, Heremans Y etal. A comprehensive analysis of cytokine induced and nuclear factor-κB-dependent genes in primary rat pancreatic beta-cells. J Biol Chem 2001; 276:48879-86.
7. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005; 54:S97-107.
8. Gurzov EN, Eizirik DL. Bcl-2 proteins in diabetes: mitochondrial pathways of β-cell death and dysfunction. Trends Cell Biol 2011; 21:424-31.
9. Tabatabaie T, Waldon AM, Jacob JM, Floyd RA, Kotake Y. COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice. Biochem Biophys Res Commun 2000; 273:699-704.
10. Persaud SJ, Burns CJ, Belin VD, Jones PM. Glucose-induced regulation of COX-2 expression in human islets of Langerhans. Diabetes 2004; 53:S190-2.
11. Han X, Chen S, Sun Y, Nadler JL, Bleich D. Induction of cyclooxygenase-2 gene in pancreatic beta-cells by 12-lipoxygenase pathway product 12-hydroxyeicosatetraenoic acid. Mol Endocrinol 2002; 16:2145-54.
12. Sandler S, Andersson AK, Barbu A etal. Novel experimental strategies to prevent the development of type 1 diabetes mellitus. Ups J Med Sci 2000; 105:17-34.
13. Ortis F, Pirot P, Naamane N etal. Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia 2008; 51:1213-25.
14. Mehmeti I, Lenzen S, Lortz S. Modulation of Bcl-2-related protein expression in pancreatic beta cells by pro-inflammatory cytokines and its dependence on the antioxidative defense status. Mol Cell Endocrinol 2011; 332:88-96.
15. Costes S, Broca C, Bertrand G etal. ERK1/2 control phosphorylation and protein level of cAMP-responsive element-binding protein: a key role in glucose-mediated pancreatic beta-cell survival. Diabetes 2006; 55:2220-30.
16. Schuppin GT, Pons S, Hügl S etal. A specific increased expression of insulin receptor substrate 2 in pancreatic beta-cell lines is involved in mediating serum-stimulated beta-cell growth. Diabetes 1998; 47:1074-85.
17. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3:791-800.
18. Cvetkovic I, Stosic-Grujicic S. Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. Int Immunopharmacol 2006; 6:1527-34.
19. Flaster H, Bernhagen J, Calandra T, Bucala R. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007; 21:1267-80.
20. Stosic-Grujicic S, Stojanovic I, Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev 2009; 8:244-9.
21. Bojunga J, Kusterer K, Bacher M, Kurek R, Usadel KH, Renneberg H. Macrophage migration inhibitory factor and development of type-1 diabetes in non-obese diabetic mice. Cytokine 2003; 21:179-86.
22. Cvetkovic I, Al-Abed Y, Miljkovic D etal. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005; 146:2942-51.
23. Waeber G, Calandra T, Roduit R etal. Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1997; 94:4782-7.
24. Taylor JA, Zhu Q, Irwin B etal. Null mutation in macrophage migration inhibitory factor prevents muscle cell loss and fibrosis in partial bladder outlet obstruction. Am J Physiol Renal Physiol 2006; 291:F1343-53.
25. Yao K, Shida S, Selvakumaran M etal. Macrophage migration inhibitory factor is a determinant of hypoxia-induced apoptosis in colon cancer cell lines. Clin Cancer Res 2005; 11:7264-72.
26. Chagnon F, Metz CN, Bucala R, Lesur O. Endotoxin-induced myocardial dysfunction: effects of macrophage migration inhibitory factor neutralization. Circ Res 2005; 96:1095-102.
27. Inácio AR, Ruscher K, Leng L, Bucala R, Deierborg T. Macrophage migration inhibitory factor promotes cell death and aggravates neurologic deficits after experimental stroke. J Cereb Blood Flow Metab 2011; 31:1093-106.
28. Lue H, Thiele M, Franz J etal. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007; 26:5046-59.
29. Taranto E, Xue JR, Morand EF, Leech M. Modulation of expression and cellular distribution of p21 by macrophage migration inhibitory factor. J Inflamm (Lond) 2009; 6:24-34.
30. Saksida T, Stosic-Grujicic S, Timotijevic G, Sandler S, Stojanovic I. Macrophage migration inhibitory factor deficiency protects pancreatic islets from palmitic acid-induced apoptosis. Immunol Cell Biol 2011; doi: 10.1038/icb.2011.89.
31. Toso C, Serre-Beinier V, Emamaullee J etal. The role of macrophage migration inhibitory factor in mouse islet transplantation. Transplantation 2008; 86:1361-9.
32. Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D etal. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol 2008; 215:665-75.
33. Fingerle-Rowson G, Petrenko O, Metz CN etal. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci USA 2003; 100:9354-59.
34. Rydgren T, Sandler S. Efficacy of 1400 W, a novel inhibitor of inducible nitric oxide synthase, in preventing interleukin-1beta-induced suppression of pancreatic islet function in vitro and multiple low-dose streptozotocin-induced diabetes in vivo. Eur J Endocrinol 2002; 147:543-51.
35. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
36. Acharya JD, Ghaskadbi SS. Islets and their antioxidant defense. Islets 2010; 2:225-35.
37. Ribaux P, Ehses JA, Lin-Marq N etal. Induction of CXCL1 by extracellular matrix and autocrine enhancement by interleukin-1 in rat pancreatic beta-cells. Endocrinology 2007; 148:5582-90.
38. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44:2115-33.
39. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 2010; 21:261-7.
40. Robertson RP. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes 1998; 47:1379-83.
41. Tran PO, Gleason CE, Poitout V, Robertson RP. Prostaglandin E(2) mediates inhibition of insulin secretion by interleukin-1 beta. J Biol Chem 1999; 274:31245-8.
42. Heitmeier MR, Kelly CB, Ensor NJ etal. Role of cyclooxygenase-2 in cytokine-induced beta-cell dysfunction and damage by isolated rat and human islets. J Biol Chem 2004; 279:53145-51.
43. -/-). Diabetes 2000; 49:1116-22.